Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 14/20 | 0.62 |
| ▸ | MTOR | P42345 | 1/20 | 0.49 |
| ▸ | FKBP4 | Q02790 | 1/20 | 0.49 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5368168 | 0.98 | FKBP1A (0.64) | FKBP1AMTORFKBP4FKBP5ALDH1A1 | |
| SCHEMBL5375908 | 0.97 | FKBP1A (0.58) | FKBP1AMTORFKBP4FKBP5 | |
| SCHEMBL5364216 | 0.94 | FKBP1A (0.60) | FKBP1AMTORFKBP4FKBP5 | |
| SCHEMBL5365881 | 0.94 | FKBP1A (0.59) | FKBP1AMTORFKBP4FKBP5 | |
| SCHEMBL5373037 | 0.93 | FKBP1A (0.53) | FKBP1A | |
| SCHEMBL5369696 | 0.88 | FKBP1A (0.66) | FKBP1AMTORFKBP4FKBP5 | |
| SCHEMBL5365886 | 0.83 | FKBP1A (0.52) | FKBP1A | |
| SCHEMBL5364010 | 0.83 | FKBP1A (0.64) | FKBP1AMTORFKBP4FKBP5 | |
| SCHEMBL14423330 | 0.82 | FKBP1A (0.51) | FKBP1A | |
| SCHEMBL5365865 | 0.81 | FKBP1A (0.50) | FKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7253169-B2 | Aza compounds, pharmaceutical compositions and methods of use | GLIAMED, INC. (US) | 2007-08-07 | — | — | US | claimed |
| US-20020028814-A1 | Aza compounds, pharmaceutical compositions and methods of use | GLIAMED, INC. | 2002-03-07 | — | — | US | claimed |
| US-7253169-B2 | Aza compounds, pharmaceutical compositions and methods of use | GLIAMED, INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-7253169-B2 | Aza compounds, pharmaceutical compositions and methods of use | GLIAMED, INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-7253169-B2 | Aza compounds, pharmaceutical compositions and methods of use | GLIAMED, INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-6417189-B1 | DRUGS WITH PYRAZOLE KETONE DERIVATIVES | GPI NIL HOLDINGS, INC. | 2002-07-09 | — | — | US | disclosed |
| US-20020028814-A1 | Aza compounds, pharmaceutical compositions and methods of use | GLIAMED, INC. | 2002-03-07 | — | — | US | disclosed |
| WO-2001079177-A1 | CYCLIC DIAZA COMPOUNDS FOR TREATING NEURODEGENERATIVE DISORDERS | GPI NIL HOLDINGS, INC. (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028814-A1 | Aza compounds, pharmaceutical compositions and methods of use | GRIN3A, CHRNA5, GRIN3B | FKBP1A 1238/4885MTOR 1723/4885FKBP4 1424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.